Abstract
Antibacterial and clinical studies were performed on grepafloxacin (GPFX), a newly developed quinolone antibacterial drug, and the following results were obtained.
The antibacterial activity of GPFX was compared with those of norfloxacin (NFLX), ofloxacin (OFLX), and ciprofloxacin (CPFX). Against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli, and Klebsiella pneumoniae, the effect of GPFX was superior to those of NFLX, OFLX, and CPFX, but the effect of GPFX against Pseudomonas aeruginosa was about one rank inferior to that of CPFX but superior to NFLX and OFLX.
In the clinical study, 10 patients (including 1 case of acute pharyngolaryngitis, 4 of acute bronchitis, 2 of acute pyelonephritis, 1 of acute cystitis, and 2 of chronic complicated urinary infection) were administered GPFX at a dose of 200-300 mg once or twice daily for 3-15 days. The clinical result was excellent in 1 case, effective in 5 cases, ineffective in 2 cases and unevaluable in 2 cases.
In regard to its safety, adverse reactions were noted in 2 cases: nausea and headache in 1 case and thirst in the other. Abnormal laboratory values were observed only in 1 case as slightly increased GPT and Al-p. These side effects and abnormal laboratory values were, however, mild in degree with no problem from the clinical standpoint.
